Is Eltrombopag/Eltrombopag included in medical insurance?

As ofMarch 2024,The original drug Eltrombopag/Eltrombopag has passed the relevant regulations of the National Medical Insurance Administration and entered the scope of Class B medical insurance reimbursement. Patients who meet the indications can be reimbursed through the national medical insurance. Patients who do not meet the medical insurance reimbursement conditions can only purchase the drug at their own expense, and the price is still relatively expensive.

The marketed uses of eltrombopaginclude: to increase platelet count; or to treat immune thrombocytopenia (ITP); or to treat aplastic anemia. In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to certain receptors (targets) in the bone marrow. The active substance in eltrombopag eltrombopag can also attach to and stimulate the thrombopoietin receptor. This increases platelet production and improves platelet counts. Eltrombopag is available as tablets and powder, and can be made into a suspension (liquid) for oral administration. This medication is available by prescription only, and treatment should be initiated and supervised by a physician experienced in treating blood disorders or chronic hepatitis C and its complications.

The dose of eltrombopag depends on the patient's age and the disease being treated, and is adjusted as needed to maintain appropriate platelet levels. Eltrombopag may cause hepatotoxicity, particularly when combined with interferon and ribavirin in patients with chronic hepatitis C (which may increase the risk of hepatic decompensation), and there have been reports of skin-related adverse events such as hyperpigmentation and yellowing of the skin. Therefore, if patients have any adverse reactions or concerns while using eltrombopag, they should consult a doctor and adjust or discontinue the drug under the guidance of a doctor.